Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | SurVaxM: A vaccine combined with chemo/radiotherapy for glioblastoma

Manmeet Ahluwalia • 18 Jul 2019
ASCO 2019
Brain Tumor Glioblastoma Nivolumab Veliparib
CheckMate 548

Speaking from the American Society of Hematology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Manmeet Singh Ahluwalia, MD, FACP, of the Cleveland Clinic, Cleveland, OH, discusses an update of the clinical phase II trial of the survivin based vaccine, SurVaxM. Here, Dr Ahluwalia explains how, when used in combination with chemotherapy and radiotherapy to treat newly diagnosed glioblastoma multiforme (GBM), SurVaxM is shown to increase overall survival from the day of SurVaxM administration in both patients with MGMT-Unmethylated GBM and MGMT-Methylated GBM.

More from Manmeet Ahluwalia

The emergence of targeted therapies and ICIs for brain metastasis
1:23
The emergence of targeted therapies and ICIs for brain metastasis
Manmeet Ahluwalia • 30 May 2025
DART: nivolumab and ipilimumab in rare cancers and brain metastases
2:33
DART: nivolumab and ipilimumab in rare cancers and brain metastases
Manmeet Ahluwalia • 30 May 2025
Assessing MB-FUS in the LIMITLESS and LIBERATE trials
2:40
Assessing MB-FUS in the LIMITLESS and LIBERATE trials
Manmeet Ahluwalia • 30 May 2025
Transformative potential of CAR-T cell therapy: current challenges and future Directions
3:17
Transformative potential of CAR-T cell therapy: current challenges and future Directions
Manmeet Ahluwalia • 8 Mar 2024

Related Videos

Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
0:58
Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
1:51
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
1:32
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
Sylvia Kurz • 31 May 2026
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
1:04
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
Sylvia Kurz • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals